Advanced Medical Optics, Inc. Announces Filing Of Amendment To Registration Statement On Form S-3

SANTA ANA, Calif., Nov. 15 /PRNewswire-FirstCall/ -- Advanced Medical Optics, Inc. (AMO) today announced that it has filed with the Securities and Exchange Commission (SEC) a pre-effective amendment to its registration statement on Form S-3, originally filed on August 5, 2005. The registration statement relates to the resale by holders of AMO’s 1.375% Convertible Senior Subordinated Notes due 2025, and the shares of AMO’s common stock issuable upon conversion of the notes, and includes previously disclosed pro forma information regarding AMO’s acquisition of VISX, Incorporated on May 27, 2005, updated through the period ended September 30, 2005. AMO’s initial issuance of the notes, in an aggregate principal amount of $150 million, was completed on July 18, 2005. A written prospectus, when available, meeting the requirements of Section 10 of the Securities Act may be obtained from AMO at 1700 E. St. Andrew Place, Santa Ana, California 92705, Attention: Investor Relations.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO )

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Advanced Medical Optics (AMO)

AMO is a global medical device leader focused on the discovery and delivery of innovative vision technologies that optimize the quality of life for people of all ages. Products in the ophthalmic surgical line include intraocular lenses, laser vision correction systems, phacoemulsification systems, viscoelastics, microkeratomes and related products used in cataract and refractive surgery. AMO owns or has the rights to such ophthalmic surgical product brands as ReZoom(TM), Phacoflex(R), Clariflex(R), Array(R), Sensar(R), CeeOn(R), Tecnis(R) and Verisyse(TM) intraocular lenses, STAR S4(TM) laser vision correction system, WaveScan Wavefront(R) System, CustomVue(TM) procedure, Sovereign(R) and Sovereign(R) Compact(TM) phacoemulsification systems with WhiteStar(TM) technology, Amadeus(TM) and Amadeus(TM) II microkeratomes, Healon(R) and Vitrax(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the contact lens care line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting drops. Among the contact lens care product brands the company possesses are COMPLETE(R) Moisture PLUS(TM), COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(R) and blink(TM) branded products. Amadeus is a licensed product of, and a trademark of, SIS, Ltd. AMO is based in Santa Ana, California, and employs approximately 3,500 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company’s Web site at www.amo-inc.com.

Investor Contact: Sheree Aronson (714) 247-8290 sheree.aronson@amo-inc.com Media Contact: Steve Chesterman (714) 247-8711 steve.chesterman@amo-inc.com

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comAdvanced Medical Optics, Inc.

CONTACT: Investors, Sheree Aronson, +1-714-247-8290,sheree.aronson@amo-inc.com, or Media, Steve Chesterman, +1-714-247-8711,steve.chesterman@amo-inc.com, both of Advanced Medical Optics, Inc.

MORE ON THIS TOPIC